KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3/rusazvir4], the company’s …
Tag Archives: International Liver Congress
April, 2017
-
24 April
Bristol-Myers Squibb’s Investigational NASH Drug Demonstrates Positive Results in Phase 2 Trial
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (F1-F3). The study achieved its primary endpoint of significant reduction in …
-
21 April
Gilead Announces Positive Proof-of-Concept Data for its NASH Candidate
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from an open-label, proof-of-concept study evaluating GS-0976, an investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH). The data, from ten patients treated with GS-0976 20 mg taken orally once daily for 12 weeks, indicated that treatment …
-
21 April
AbbVie’s Pan-Genotypic HCV Regimen Achieves a 99% Cure Rate in Late-Stage Study
AMSTERDAM, April 20, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A) achieved sustained virologic response at 12 weeks post-treatment (SVR12) with its …
April, 2016
-
15 April
AbbVie’s Pan-Genotypic Regimen Shows Promise in Pre-Treated Patients
BARCELONA, April 15, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) …
April, 2015
-
23 April
Gilead and Merck Present Positive Data for Next-Generation Hepatitis C Drug Regimens
At The International Liver Congress, both Gilead Sciences and Merck announced positive results from hepatitis C trials, evaluating their next-generation hepatitis C combo drugs. Gilead revealed preclinical data and results from a mid-stage study supporting the development of its investigational all-oral, three-drug regimen of Sovaldi (sofosbuvir), the investigational NS5A inhibitor …